50 results on '"Vojnic, Morana"'
Search Results
2. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
3. The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma
4. Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials
5. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
6. Prioritizing Radiation and Targeted Systemic Therapies in Patients with Resected Brain Metastases from Lung Cancer Primaries with Targetable Mutations: A Report from a Multi-Site Single Institution.
7. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
8. RADT-03. A CASE OF PARTIAL HIPPOCAMPAL-AVOIDANCE WHOLE BRAIN RADIOTHERAPY IN A PATIENT WITH METASTATIC INFILTRATION OF THE LEFT HIPPOCAMPUS
9. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
10. SDPS-25 COMPARISON OF MOLECULAR ALTERATIONS BETWEEN SYSTEMIC AND CNS METASTATIC SITES REVEALSMUTATIONAL DISCORDANCES
11. Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
12. Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models
13. Supplementary Figure from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
14. Data from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
15. Data from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
16. Supplementary Figures from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
17. Supplementary Table from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
18. Supplementary Methods from Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
19. Intraoperative awake language mapping correlates to preoperative connectomics imaging: an instructive case
20. Supplementary Figure S3 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
21. Figure S4 from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
22. Figure S2 from Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
23. Supplementary Materials and Methods from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
24. Supplementary Methods from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
25. Mature Type T-Lymphoblastic Leukemia/Lymphoma Presenting With Isolated Central Nervous System Symptomatology in a Patient With Giant Cell Arteritis on Long-Term Steroid Treatment
26. MODL-01. TRACTABLE PATIENT-DERIVED MODELS FOR PRECLINICAL THERAPEUTIC STUDIES OF CNS METASTASES
27. 173: EMPIRIC THROMBOLYSIS DURING A CARDIAC ARREST FOR A PATIENT WITH A RIGHT HEART THROMBUS
28. Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases.
29. A Rapidly Accumulating Effusion in an Immunocompetent Woman
30. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
31. A 33-Year-Old Man With Chest Pain
32. Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling
33. Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations
34. Brain metastasis screening in the molecular age.
35. Low-grade B-cell lymphomas in the spinal epidural space: A case series and review of the literature
36. Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions
37. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
38. RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
39. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
40. Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach
41. Landscape of targetable alterations discovered by next generation sequencing demonstrates the role a community hospital can play in precision-guided oncology: Experience from Lenox Hill Hospital.
42. LPTO-04. GENERATION AND CHARACTERIZATION OF PATIENT-DERIVED PRECLINICAL MODELS FROM TUMOR CELLS ISOLATED FROM CEREBROSPINAL FLUID
43. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
44. Serendipitous Finding of Asymptomatic Babesiosis in a Patient With Symptomatic Thrombocytopenia
45. Abstract 1826: Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
46. Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
47. Acquired BRAF fusions as a mechanism of resistance to EGFR therapy.
48. Acquired BRAFRearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
49. Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do?
50. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.